Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats

L Bokser, B Szende, A V Schally, L Bokser, B Szende, A V Schally

Abstract

The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats. D-Trp6-LH-RH microcapsules were injected once a month for 3 months, in a dose calculated to release 25 micrograms day-1. Control animals received the injection vehicle. Sixty days after the first injection of microcapsules, cyclophosphamide was given at a loading dose of 50 mg kg-1 followed by 5 mg kg-1 day-1 for 30 days, while the treatment with D-Trp6-LH-RH was continued. When the ovaries were examined 3 months and 5 months after discontinuation of treatment, a significant reduction in the total number of follicles (P less than 0.01) was found in non-pretreated animals given cyclophosphamide. This reduction affected mainly follicles larger than 100 microns. An irreversible disintegration and destruction of granulosa cells was also observed in this group. In animals pretreated with D-Trp6-LH-RH, administration of cyclophosphamide caused no reduction in the number and diameter of follicles. Thus, the treatment with D-Trp6-LH-RH microcapsules before and during chemotherapy prevented the ovarian injury inflicted by cyclophosphamide. The suppression of gonadal function by LH-RH analogues could be possibly utilised for the protection of the ovaries against damage caused by cytotoxic drugs.

References

    1. Biol Reprod. 1978 Oct;19(3):597-605
    1. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2329-33
    1. Cancer. 1980 Apr 15;45(8):2030-7
    1. Int J Gynaecol Obstet. 1980;18(5):318-24
    1. Blood. 1981 Oct;58(4):849-51
    1. J Reprod Fertil. 1982 Nov;66(2):451-6
    1. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1459-62
    1. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1547-51
    1. Crit Rev Oncol Hematol. 1988;8(2):153-71
    1. Proc Soc Exp Biol Med. 1968 Jul;128(3):807-11
    1. J Reprod Fertil. 1974 Feb;36(2):345-52
    1. Clin Biochem. 1974 Sep;7(3):193-201
    1. J Reprod Fertil. 1975 Dec;45(3):567-74
    1. Science. 1974 Sep 13;185(4155):949-51
    1. Cancer. 1978 Jun;41(6):2084-7
    1. J Reprod Fertil. 1989 Mar;85(2):569-74
    1. Int J Pept Protein Res. 1988 Dec;32(6):425-35
    1. Acta Endocrinol (Copenh). 1989 Jul;121(1):55-60
    1. Arzneimittelforschung. 1990 Feb;40(2 Pt 1):111-8
    1. J Endocrinol. 1961 Feb;21:497-509
    1. Proc Natl Acad Sci U S A. 1985 May;82(9):2975-9
    1. J Urol. 1985 Jul;134(1):187-90
    1. Cancer Res. 1985 Aug;45(8):3651-6
    1. Cancer Res. 1986 Apr;46(4 Pt 2):1909-14
    1. Endocr Rev. 1986 Feb;7(1):115-24
    1. Fertil Steril. 1986 Apr;45(4):443-59
    1. Cancer Res. 1987 Feb 15;47(4):1093-7
    1. Proc Natl Acad Sci U S A. 1987 Feb;84(3):851-5
    1. Cancer Res. 1987 Mar 1;47(5):1344-7
    1. Cancer Res. 1987 May 1;47(9):2340-3
    1. Cancer Res. 1987 Oct 1;47(19):5005-8
    1. JAMA. 1988 Apr 8;259(14):2123-5
    1. Cancer Res. 1988 Apr 15;48(8):2174-8
    1. JAMA. 1979 Oct 26;242(17):1877-81

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel